| Debra Richmond, | |
|
5320 W 154th St, Leawood, KS 66224-3657 | |
| (913) 558-8709 | |
| Not Available |
| Full Name | Debra Richmond |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 5320 W 154th St, Leawood, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427580901 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1-10918 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Debra Richmond, 5320 W 154th St, Leawood, KS 66224-3657 Ph: (913) 558-8709 | Debra Richmond, 5320 W 154th St, Leawood, KS 66224-3657 Ph: (913) 558-8709 |
News Archive
Impax Laboratories, Inc. today announced that the European Commission has granted marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease.
The Food and Drug Administration (FDA) has approved Merit Medical Systems, Inc.'s phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere™ Microspheres (hqTACE) for delivery of doxorubicin. The clinical trial will involve U.S. and international interventional radiologists who treat patients with localized, unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.
By 2025 some 500 million people will be living with osteoporosis, a chronic disease which weakens bones and leaves older adults at risk of a fragility fracture - a broken bone which typically occurs after a low-trauma fall. As a result, an estimated 13.5 million fragility fractures will occur worldwide.
Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.
› Verified 8 days ago
Dr. Jack R Bates, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9521 Mission Rd, Leawood, KS 66206 Phone: 913-383-2823 | |
Catherine Khalil, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4701 Town Center Dr, Leawood, KS 66211 Phone: 913-469-4014 | |
Mary K Wilson, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2305 W 123rd Ter, Leawood, KS 66209 Phone: 816-588-2215 | |
Ines Fomaga Tsotezo, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8316 Overbrook Rd, Leawood, KS 66206 Phone: 316-768-0098 | |
Dr. David John Hanson, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12122 State Line Rd, Leawood, KS 66209 Phone: 913-345-9377 | |
Tiana Williams, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5001 W 135th St, Leawood, KS 66224 Phone: 913-851-9903 | |
Dr. Jason S Kim, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12724 Sagamore Rd, Leawood, KS 66209 Phone: 858-220-2615 |